Long-term study of a new heart valve for aortic stenosis
Part of Heart & circulation clinical trials.
This study is testing a new heart valve called the SAPIEN 3 Ultra RESILIA valve for people with severe aortic stenosis. Researchers want to see how well it works and how safe it is over 10 years after a minimally invasive valve replacement procedure called TAVI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You have been diagnosed with severe aortic stenosis (a narrowing of your heart's main valve)
- You are scheduled to have a TAVI procedure through your leg artery to replace your own valve
- You are willing to come to the hospital for check-ups for up to 10 years after the procedure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how safe and effective the SAPIEN 3 valve is for patients in China who have a specific type of bicuspid aortic valve (Type-0) that is severely narrowed. If you have severe aortic stenosis and meet the criteria, this treatment might be an option for you.
This trial studies a new “valve-in-valve” procedure to treat a failing aortic bioprosthetic valve. It may help people improve blood flow through the heart valve and reduce valve-related problems.
This study follows patients with severe aortic stenosis who get a new heart valve (the SAPIEN 3 Ultra RESILIA) through a less invasive procedure (TAVR). Researchers want to see how well this valve works over time using special heart ultrasound tests.
This study compares regular monitoring (“clinical surveillance”) versus replacing the aortic valve using a minimally invasive procedure called TAVR for people with moderate aortic stenosis. It aims to see which approach better reduces symptoms or heart damage over time.
This study checks how well an aortic valve replacement works many years after the procedure. It may help doctors understand long-term valve function and identify people who might need closer monitoring.
This trial compares two of the newest transcatheter aortic valve devices—the SAPIEN 3 Ultra Resilia and Evolut FX—to see which works better for patients with severe aortic stenosis (a narrowed aortic valve). Both devices are placed through a catheter without open surgery.
Hear when a new Aortic Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.